Phathom Pharmaceuticals (PHAT) Income towards Parent Company (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Income towards Parent Company data on file, last reported at -$48.0 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 49.13% year-over-year to -$48.0 million in Q1 2026; TTM through Mar 2026 was -$207.7 million, a 45.18% increase from a year earlier, with the FY2025 full-year figure at -$233.5 million, up 54.9% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$48.0 million, down from -$21.1 million in the prior quarter.
• Over the last five years, Income towards Parent Company for PHAT reached as high as -$21.1 million in Q4 2025 and fell as low as -$118.7 million in Q3 2024.
• Historically, Income towards Parent Company has averaged -$64.0 million across 5 years, with a median of -$51.1 million in 2022.
• Across the five-year window, Income towards Parent Company plunged 175.73% in 2024 and soared 71.62% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$49.2 million in 2022, then tumbled by 103.99% to -$100.3 million in 2023, then rose by 25.7% to -$74.5 million in 2024, then surged by 71.62% to -$21.1 million in 2025, then plunged by 126.89% to -$48.0 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$48.0 million in Q1 2026, -$21.1 million in Q4 2025, and -$55.2 million in Q3 2025.